Imidazolidine Carboxamide Derivatives as P2X7 Modulators
AssigneeGlaxo Group Limited
InventorsPaul John Beswick, David Kenneth Dean, Robert James Gleave, Andrew Peter Moses, Daryl Simon Walter
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.
Claims37
A compound of formula (I):
- wherein:
- R1 represents hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkylmethyl-, pyridinylmethyl- or benzyl, and wherein any of said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkylmethyl-, pyridinylmethyl- or benzyl is optionally substituted with 1, 2 or 3 halogen atoms;
- or an unsubstituted phenyl;
- R2 represents hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkylmethyl-, —(CRxRy)n—NR11R12, C6-10 arylmethyl-, heterocyclyl-(CRxRy)n— or heteroaryl-(CRxRy)n—;
- and wherein any of said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkylmethyl-, C6-10 arylmethyl-, heterocyclyl-(CRxRy)n— or heteroaryl-(CRxRy)n— is optionally substituted with 1, 2 or 3 halogen atoms or C1-6 alkyl groups, or the heteroaryl-(CRxRy)n— is optionally substituted on the heteroaryl ring with one C1-3 alkoxy (e.g. methoxy), cyano or trifluoromethyl group;
- R3, R4 and R5 independently represent hydrogen, fluorine or methyl;
- and
- R6, R7, R8, R9 and R10 independently represent hydrogen, halogen, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or phenyl, and any of said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or phenyl is optionally substituted with 1, 2 or 3 halogen atoms;
- or R9 and R10 together with the carbon atoms to which they are attached form a benzene ring which is optionally substituted with 1, 2 or 3 halogen atoms;
- Rx and Ry independently represent hydrogen or C1-6 alkyl;
- R11 and R12 independently represent hydrogen or C1-6 alkyl;
- n represents an integer from 0 to 4;
- with the proviso that when R6 and R10 independently represent hydrogen or fluorine, at least one of R7, R8 and R9 is a halogen atom, or only one of R7, R8 and R9 is a CF3 group;
- or a pharmaceutically acceptable salt thereof.
(canceled)
(canceled)
6-7. (canceled)
(canceled)
(canceled)
16-17. (canceled)
(canceled)
23-24. (canceled)
27-33. (canceled)
A compound which is N-[(2,4-dichlorophenyl)methyl]-3-methyl-2-oxo-4-imidazolidinecarboxamide of the formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.